Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.48 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23727584 | 0.94 | HPGD (0.57) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1980161 | 0.94 | HPGD (0.50) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL12205292 | 0.94 | HPGD (0.57) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL13820 | 0.92 | MAPT (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL1968766 | 0.92 | MAPT (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL56905 | 0.92 | MAPT (0.53) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL2087178 | 0.91 | HPGD (0.48) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3937411 | 0.89 | MAPT (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| Piperidine SCHEMBL2684524 | 0.88 | HPGD (0.52) | HPGDRECQLEPHX1USP2SMN1; SMN2 | |
| SCHEMBL31209769 | 0.87 | MAPT (0.47) | HPGDRECQLEPHX1USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1236 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514811-A | Synthesis method of 2, 7-diaza-spiro [3,5] nonane-2-tert-butyl formate | 药璞(上海)医药科技有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-113024530-B | Isatin-1, 2, 4-oxadiazole compound and preparation method and application thereof | 合肥工业大学 | 2023-07-18 | — | — | CN | claimed |
| CN-113024530-A | Isatin-1, 2, 4-oxadiazole compound and preparation method and application thereof | 合肥工业大学 | 2021-06-25 | — | — | CN | claimed |
| CN-107646855-B | Application of thiazole compound containing piperidine in preparation of bactericide and preparation method thereof | 浙江工业大学 | 2020-07-07 | — | — | CN | claimed |
| EP-4027995-B1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS SATURN INC (US) | 2026-05-27 | — | — | EP | disclosed |
| CN-116546990-B | CD73 inhibitor and pharmaceutical application thereof | RISEN (SUZHOU) PHARMA TECH Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4743078-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3746436-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132259-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, ARTICLE, AND METHOD FOR MANUFACTURING ARTICLE | AGC Inc. (JP) | 2026-05-14 | — | — | US | disclosed |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2026-05-07 | — | — | US | disclosed |
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4714446-A2 | PHARMACEUTICAL COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-03-25 | — | — | EP | disclosed |
| WO-2000076972-A1 | N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000059502-A1 | PYRROLIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | MERCK & CO., INC. (US) | 2000-10-12 | — | — | WO | disclosed |
| WO-2000039125-A1 | PIPERIDINES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
| EP-1002794-A1 | 4-[(Aryl)(aryloxy)methyl]piperidine derivatives and their use as serotonin and/or noradrenaline reuptake inhibitors | FAES, Fabrica Espanola de Productos Quimicos y Farmaceuticos, S.A. (ES) | 2000-05-24 | — | — | EP | disclosed |
| EP-0944388-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1999-09-29 | — | — | EP | disclosed |
| US-5891889-A | Inhibitors of farnesyl-protein transferase | MERCK & CO., INC. (US) | 1999-04-06 | — | — | US | disclosed |
| WO-1997038665-A2 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1997-10-23 | — | — | WO | disclosed |
| US-4760158-A | Cyclic halonitriles | JOHN WYETH & BROTHER LIMITED (GB) | 1988-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116881-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | KIF2C, KIF5B, KIF5C | HPGD 4099/4885RECQL 382/4885EPHX1 4528/4885 |
| US-20260124214-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | CBR1, NR3C1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HPGD 1203/4885RECQL 1812/4885EPHX1 1118/4885 |
| US-20260132259-A1 | COMPOUND, COMPOSITION, SURFACE TREATMENT AGENT, ARTICLE, AND METHOD FOR MANUFACTURING ARTICLE | MSR1, SEM1, TAS2R1 | HPGD 4864/4885RECQL 342/4885EPHX1 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.